|
EP3813867A1
|
|
Treatment of lymmphatic metastases
|
|
CA3101097A1
|
|
Treatment of gaucher disease
|
|
US2021046149A1
|
|
Bifunctional blood brain therapies
|
|
EP3402528A1
|
|
Blood-brain barrier vector compounds and conjugates thereof
|
|
US2018009898A1
|
|
Antibodies against p97 and conjugates thereof
|
|
AU2015271882A1
|
|
p97-antibody conjugates and methods of use
|
|
EP3137610A2
|
|
P97-polynucleotide conjugates
|
|
CA2935805A1
|
|
P97-ids fusion proteins
|
|
WO2015117121A1
|
|
P97 fusion proteins
|
|
AU2014312190A1
|
|
CNS-targeted conjugates of antibodies
|
|
BR112015022416A2
|
|
p97 fragments and their uses
|
|
CA2880162A1
|
|
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
AU2012294673A1
|
|
p97 fragments with transfer activity
|
|
AU2012278944A1
|
|
p97-antibody conjugates and methods of use
|
|
AU2003222568A1
|
|
Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
